Now I have all the information needed. Let me synthesize the final review.

## Summary

ProteinVista introduces a 3D CNN operating on voxelized full-atom protein structures (123M parameters), pre-trained on ~500K AlphaFold-2 structures via contrastive alignment to ESM-2. On three binding-related tasks (enzyme-substrate classification, transporter-substrate classification, drug-target IC50 regression), it matches or exceeds ESM-2 models (150M-650M parameters) while using orders of magnitude less pre-training data and compute. The paper also demonstrates that ensemble with ESM-2 yields further gains, supporting complementarity between sequence and structure representations.

## Strengths

1. **Strong empirical results on binding tasks with proper controls for the ESM-2 comparison.** ProteinVista achieves R²=0.69 on IC50 prediction vs. ESM-2_650M's 0.61 (p < 10⁻³⁰⁴, Wilcoxon signed-rank test). The direct comparison controls for prediction head architecture, small-molecule embeddings, and training protocol (Section 3.1, lines 93-99), isolating the effect of the protein encoder.

2. **Dramatic compute and data efficiency.** Pre-training on ~500K structures in 48 hours on 4×A100 GPUs (≈1% of the GPU-hours ESM-2_650M required on 128×H100 GPUs over 7 days with 250M sequences). The model processes 1,000 proteins for training in ~20s on a single A100 (Section 4.3, lines 486-506). While the exact runtime numbers need clarification (see Weaknesses), the orders-of-magnitude efficiency advantage is credible.

3. **Ablation studies systematically validate design choices.** The paper ablates contrastive vs. Rosetta pre-training (+1.0% R² gain), voxel resolution (+1.1% for 1.0Å vs 1.5Å), multi-view inference (+6.4% for 5 vs. 1 view), and training augmentations (Section 4.2, Figure 2e). These ablations correctly isolate individual components.

4. **Honest and informative failure analysis.** The GO term result (F₁ₘₐₓ 0.57 vs. ESM-2's 0.62) is reported and discussed candidly (Section 3.4). The analysis of performance by sequence identity, structural similarity, and pLDDT confidence (Section 4.1) provides nuanced insight into when structure helps and when it does not.

5. **Statistical rigor on complementarity.** The ESM-ProteinVista ensemble's improvement over individual models on TSP/ESP is validated with McNemar's test (p < 10⁻¹³, p < 10⁻¹⁷), and the IC50 improvement over ESM-2 with Wilcoxon signed-rank test.

## Weaknesses

### Fatal
None.

### Major

1. **SOTA comparison lacks explicit split control.** In Section 3.3, the paper reports that ESM-ProteinVista_OP surpasses SPOT (TSP), ProSmith-ESP, and Fusion_ESP (ESP). However, it is not stated whether these baselines were evaluated on the *exact same* train/test splits used for ProteinVista or whether numbers are cited from original publications. The TSP and ESP datasets are from Kroll et al. (2023, 2024a), which are standard benchmarks, but the paper should explicitly confirm split identity. This makes the headline "state-of-the-art" claim unverifiable from the text as written. (Section 3.3, lines 448-454; Table 1)

2. **FLOPs/throughput numbers contain an unexplained discrepancy.** ProteinVista requires 415 GFLOPs per input vs. ESM-2_150M's 140 GFLOPs (~3×), yet processes 1,000 proteins in 20s vs. ESM-2_150M's 215s (~10× faster). The paper's explanation ("computations can be parallelized more efficiently") is plausible but undersupported. Missing details that prevent independent verification: (a) whether the 20s includes voxelization; (b) the batch sizes used for each model; (c) how FLOPs were estimated. Additionally, the embedded figure image labels panel (c) as "Inference Time" while the text and figure caption describe "training time" — a labeling inconsistency. (Section 4.3, lines 486-506; Figure 3)

### Minor

1. **Tension between contrastive pre-training and the complementarity claim is not discussed.** ProteinVista is pre-trained to align its embedding space with ESM-2 via InfoNCE loss (Section 2.3), yet the paper claims the model captures *complementary* structure-specific information. While the ensemble evidence (p < 10⁻¹³) empirically demonstrates complementarity — and the Rosetta-only ablation (which avoids ESM-2 alignment entirely) performs nearly as well — the paper does not address how a model explicitly trained to mirror ESM-2's representation space can learn features orthogonal to it, or what fraction of its representation is structure-specific vs. aligned. This is a reasoning gap that weakens the narrative.

2. **IC50 ensemble degradation unexplained.** ProteinVista alone achieves R²=0.69 while the ESM-ProteinVista ensemble achieves R²=0.68. The paper states "the sequence model has nothing left to contribute," which does not explain why averaging *degrades* performance below the better individual model. A per-sample error analysis or correlation analysis between the two models' predictions would clarify this. (Table 2, lines 123-124, 437)

3. **ESM-2 variant used as contrastive teacher is unspecified.** Section 2.3 (line 77) references "ESM-2 sequence embeddings" without stating whether ESM-2_150M or ESM-2_650M was used. This affects interpretation of what knowledge was distilled. (Section 2.3, lines 77-79)

### Trivial

- The density formula in Section 2.1 (line 61) is syntactically garbled: "its contribution to the c-channel of the voxel centered at v⃗ = exp(-‖v⃗ - r⃗‖/σ²)". The intended formula is clearly a Gaussian weighting, but the equation as written is malformed.

## Nice-to-Haves

- Adding confidence intervals for GO term F₁ₘₐₓ (0.57 vs. 0.62) would be good practice, though the gap is large enough that it is unlikely to change interpretation.
- Reporting what fraction of proteins exceed the 160³-voxel bounding box and are cropped would help assess potential failure modes for large proteins.
- A per-sample correlation plot of ProteinVista vs. ESM-2 predictions on the IC50 task would clarify the ensemble degradation.

## Removed Points

- **"Contrastive pre-training is a fatal methodological flaw"** (Harsh Critic point #1 original framing). Removed because the claim is overstated: the contrastive objective only constrains the 256-dim projected space, fine-tuning can recover structure-specific features, and the Rosetta-only ablation (no ESM alignment) shows similar performance. The ensemble results (p < 10⁻¹³) directly demonstrate complementarity. Kept as a Minor weakness (reasoning gap, not a fatal flaw).

- **"Density formula is dimensionally inconsistent"** (Harsh Critic Section 2.1 note). Removed because the garbled formula is a PDF parser artifact; the paper's original submission would contain the correct expression. Also it's a trivial formatting issue.

- **"Missing appendix/table references"** (Harsh Critic). Removed because the appendix is stripped by the PDF parser from all papers; it exists in the original submission.

- **Missing related work mentions.** Removed per instructions, as I cannot confirm existence of external work.

- **Request for larger data / more models / statistical significance on GO.** Removed as generic or scope-creep; GO task is honestly reported as a limitation.

- **Reproducibility nitpicks (hyperparameters, trivial implementation details).** Removed per filtering rules.

- **Strength: "Addressed an important problem" / "Paper is well-motivated."** Removed as generic; kept concrete strengths with specific evidence.

## Novel Insights

The reviews surface one insight the paper itself does not exploit: the IC50 ensemble degradation (R² 0.69 → 0.68 when averaging with ESM-2) could be used as a diagnostic for *when* structure information is sufficient. On the TSP/ESP tasks, the ensemble improves over either model; on IC50, it hurts. This pattern suggests a spectrum: tasks where sequence information adds noise to an already-strong structure-based prediction vs. tasks where sequence and structure contribute complementary weak signals. Characterizing where on this spectrum a given task falls — perhaps via the rank correlation between the two models' per-sample errors — would make the paper's framework predictive rather than post-hoc.

## Suggestions

1. **Clarify the SOTA split control.** Either re-run SPOT/ProSmith-ESP/Fusion_ESP on the exact same splits, or explicitly cite the original papers' splits and confirm they match. This single clarification, added to a revised version, would resolve the most serious weakness.

2. **Provide a corrected and explained runtime table.** Report: (a) whether the 20s/1000-proteins includes voxelization time; (b) batch sizes per model; (c) how FLOPs were estimated (torchprofile? theoretical peak?); (d) whether the throughput is measured during training (forward+backward) or inference-only. The figure caption should consistently say "training time" or "inference time," not both.

3. **Address the contrastive pre-training/complementarity tension directly.** One or two sentences in Section 2.3 or 5 acknowledging that the InfoNCE loss only constrains the projected 256-dim space, leaving the full 1024-dim representation free to encode structure-specific features, and noting that the Rosetta-only ablation confirms structure-only pretraining works even without ESM alignment. This would reconcile the design with the claim.

4. **Analyze the IC50 ensemble drop.** A simple scatter plot or per-sample error correlation between ProteinVista and ESM-2 predictions would clarify whether the degradation arises from negative correlation, miscalibration, or random noise.

## Score and Decision

Let me now perform the calibration.

Round 1 bracketing placed this paper between the weak anchor range (2.0-3.33, reject-level) and the strong anchor range (8.0+, high-quality accepts). The middle anchors (4.0-6.5) include mix of rejects and poster accepts.

Round 2 narrowing examined papers in the 4.5-7.5 range. The most relevant anchors:

- **ProteinAE (5.0, Accept Poster)**: Diffusion autoencoder for protein structures. Comparable quality — both have clean architecture presentation and good results, but ProteinAE's weaknesses (missing related work) are less severe than ProteinVista's split-control issue. ProteinVista has stronger evaluation with better controls. **Verdict: ProteinVista is slightly stronger.**

- **FlexRibbon (5.0, Accept Poster)**: Joint sequence-structure pretraining across 12 benchmarks. Stronger in breadth of evaluation but one reviewer gave 4 with significant concerns about evaluation scope. **Verdict: Comparable quality.**

- **SAIR (5.5, Accept Poster)**: Million-scale synthetic structure dataset. Similar level of contribution; SAIR's weaknesses (structure validation concerns) are comparable in severity to ProteinVista's SOTA split concern. **Verdict: Similar quality.**

- **ADiT (6.5, Accept Poster)**: Ambitious all-atom foundation model with diffusion transformer. More architecturally sophisticated but has data leakage concerns. ProteinVista is cleaner in evaluation but less architecturally novel. **Verdict: ProteinVista is below ADiT.**

The paper makes a solid, well-executed contribution with honest reporting and strong binding-task results. However, the SOTA split control ambiguity and the FLOPs/throughput discrepancy are meaningful issues that prevent the paper's strongest claims from being fully verifiable as submitted. These are addressable in revision.

**Final bracket determined: 5.0–6.0 → Final score: 5.5**

MY FINAL SCORE: <score>5.5</score>
MY FINAL DECISION: <decision>Accept</decision>